Name (Synonyms) | Correlation | |
---|---|---|
drug848 | Endoscopic management according to standard of care Wiki | 0.58 |
drug1756 | Palliative care assessment Wiki | 0.58 |
drug754 | Dexmethylphenidate Wiki | 0.58 |
drug874 | Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D007565 | Jaundice, NIH | 0.58 |
D002761 | Cholangitis NIH | 0.58 |
D018281 | Cholangiocarcinoma NIH | 0.58 |
D008105 | Liver Cirrhosis, Biliary NIH | 0.58 |
D041781 | Jaundice, Obstructive NIH | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002894 | Neoplasm of the pancreas HPO | 1.00 |
HP:0030153 | Cholangiocarcinoma HPO | 0.58 |
HP:0002613 | Biliary cirrhosis HPO | 0.58 |
HP:0000952 | Jaundice HPO | 0.58 |
HP:0030151 | Cholangitis HPO | 0.58 |
There are 3 clinical trials
The primary objective is to explore the impact of early palliative care on quality of life in patients with advanced pancreatic cancer. The secondary objectives are to explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer.
Description: For the primary endpoint, we will use a generalized linear model to test for a statistically significant change score between baseline and 16 weeks. We will assume a normal distribution for the change scores. Model fit will be assessed via a visual assessment of residuals and the ratio of the model deviance to its degrees of freedom.
Measure: Impact of early palliative care on quality of life in patients with advanced pancreatic cancer Time: registration to 16 weeksDescription: Secondary endpoints will include: (1) symptom control at 16 weeks as measured by the revised Edmonton Symptom Assessment Scale (ESAS-r) (a widely used and validated tool to assess symptom intensity, which is routinely completed by patients at all CCMB visits); (2) depression and anxiety at 16 weeks using the Hospital Anxiety and Depression Scale (HADS) (a 14 item scale which can be used in the outpatient setting to screen for anxiety and depression within the previous week) and the Patient Health Questionnaire (PHQ-9) (a sensitive (88%) and specific (88%) 9 question tool which incorporates diagnostic criteria for major depression); and overall survival measured from date of registration to death
Measure: To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer Time: registration to 16 weeksPancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis. However, treatment of PC in high-volume centers with the support of a multidisciplinary approach has widely demonstrated improvement both in terms of short- and long-term outcomes. The recent worldwide spread of Covid-19 pandemic significantly affected the healthcare systems of most countries in the world, particularly in red areas such as Italy, with more than 100.000 cases in a two-month time lapse. This inevitably reflected in a reorganization of hospital activities, including the diagnostic and therapeutic pathways for PC treatment. With the aim of giving an objective and real representation of the impact of Covid-19 on PC treatment, the investigator here propose a multicenter Italian observational study comparing a 6-month period before and during the Covid-19 pandemic. Only high-volume centers will be involved in the study. A comparison between the general, clinical, endoscopic and surgical outcomes will be performed by means of a global and month-by-month analysis between the two study periods.
In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
Description: Investigators will report the baseline demographic data (age, gender, nationality) of all patients.
Measure: Age, gender, nationality Time: 3 monthsDescription: Investigators will report the baseline data clinical data (indication for procedure, status of SARS-CoV-2 infection) of all patients.
Measure: Indication for procedure, status of SARS-CoV-2 infection Time: 3 monthsDescription: Investigators will report the baseline laboratory data (complete blood count and liver functions tests) of all patients.
Measure: Complete blood count and liver functions tests Time: 3 monthsDescription: Investigators will report the procedure related complications.
Measure: procedure related complications Time: 3 monthsDescription: Investigators will report wether the precautions lead to increase timing of the procedure
Measure: Effect of COVID-19 precautions on procedure time Time: 3 monthsDescription: Investigators will report wether the precautions affected staff number (increased or decreased)
Measure: Effect of COVID-19 precautions on staff number Time: 3 months